---
title: Efficacy Evaluation of Dai Dai Flower on Body Weight
nct_id: NCT04692792
overall_status: COMPLETED
phase: NA
sponsor: TCI Co., Ltd.
study_type: INTERVENTIONAL
primary_condition: Gastroenterology
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04692792.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04692792"
ct_last_update_post_date: 2021-08-04
last_seen_at: "2026-05-12T07:20:16.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy Evaluation of Dai Dai Flower on Body Weight

**NCT ID:** [NCT04692792](https://clinicaltrials.gov/study/NCT04692792)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** TCI Co., Ltd.
- **Conditions:** Gastroenterology
- **Start Date:** 2021-01-04
- **Completion Date:** 2021-06-15
- **CT.gov Last Update:** 2021-08-04

## Brief Summary

To assess the Dai Dai flower extract on body weight control

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy male or female aged between 20 and 60 years old
* Body mass index (BMI) ≥ 24 (kg/m\^2) or body fat mass ≥ 25%

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Implementation in weight loss programs, consumption drugs or supplements for weight control before 3 months of this study
* Participate weight control or fat loss human studies before 3 months of this study
* History of cardiovascular disease, liver disease, kidney disease, endocrine disease, or other major organic diseases (according to subjects reporting).
* Person who has received major surgery or bariatric surgery (according to medical history).
* Person who has received constant drug use.
* People with mental illness
```

## Arms

- **Placebo drink** (PLACEBO_COMPARATOR)
- **Dai Dai flower drink** (EXPERIMENTAL)

## Interventions

- **Placebo drink** (DIETARY_SUPPLEMENT) — consume 1 bottle (50 mL) per day for 8 weeks
- **Dai Dai flower drink** (DIETARY_SUPPLEMENT) — consume 1 bottle (50 mL) per day for 8 weeks

## Primary Outcomes

- **The change of body weight** _(time frame: Change from Baseline body weight at 8 weeks)_ — The body weight (kg) was assessed by InBody.
- **The change of BMI** _(time frame: Change from Baseline BMI at 8 weeks)_ — The BMI was assessed by InBody.

## Secondary Outcomes

- **The change of body fat mass** _(time frame: Change from Baseline body fat mass at 8 weeks)_
- **The change of visceral fat mass** _(time frame: Change from Baseline visceral fat mass at 8 weeks)_
- **The change of waist-hip ratio** _(time frame: Change from Baseline waist-hip ratio at 8 weeks)_
- **The change of basal metabolic rate** _(time frame: Change from Baseline basal metabolic rate at 8 weeks)_
- **The change of AST** _(time frame: Change from Baseline AST at 8 weeks)_
- **The change of ALT** _(time frame: Change from Baseline ALT at 8 weeks)_
- **The change of Creatinine** _(time frame: Change from Baseline creatinine at 8 weeks)_
- **The change of BUN** _(time frame: Change from Baseline BUN at 8 weeks)_
- **The change of fasting glycemia** _(time frame: Change from Baseline fasting glycemia at 8 weeks)_
- **The change of total cholesterol** _(time frame: Change from Baseline total cholesterol at 8 weeks)_
- **The change of triglyceride** _(time frame: Change from Baseline triglyceride at 8 weeks)_
- **The change of HDL-cholesterol** _(time frame: Change from Baseline HDL-cholesterol at 8 weeks)_
- **The change of LDL-cholesterol** _(time frame: Change from Baseline LDL-cholesterol at 8 weeks)_
- **The change of insulin** _(time frame: Change from Baseline insulin at 8 weeks)_
- **The change of adiponectin** _(time frame: Change from Baseline adiponectin at 8 weeks)_
- **The change of leptin** _(time frame: Change from Baseline leptin at 8 weeks)_
- **The change of IFN-γ** _(time frame: Change from Baseline IFN-γ at 8 weeks)_
- **The change of IL-2** _(time frame: Change from Baseline IL-2 at 8 weeks)_
- **The change of IL-1beta** _(time frame: Change from Baseline IL-1beta at 8 weeks)_

## Locations (1)

- China Medical University, Taichung, Taiwan

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.china medical university|taichung||taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04692792.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04692792*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*